192 related articles for article (PubMed ID: 21119513)
21. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
22. Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?
Galetta D; Rossi A; Colucci G; Gebbia V
Oncology; 2009; 77 Suppl 1():113-21. PubMed ID: 20130439
[TBL] [Abstract][Full Text] [Related]
23. Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases.
Raynaud CM; Mercier O; Commo F; Dartevelle P; Gomez-Roca C; de Montpreville V; Sabatier L; Soria JC
Lung Cancer; 2009 Aug; 65(2):144-9. PubMed ID: 19091442
[TBL] [Abstract][Full Text] [Related]
24. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array.
Hofmann HS; Bartling B; Simm A; Murray R; Aziz N; Hansen G; Silber RE; Burdach S
Oncol Rep; 2006 Sep; 16(3):587-95. PubMed ID: 16865260
[TBL] [Abstract][Full Text] [Related]
25. Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics.
Radtke J; Rezaie SG; Kugler Ch; Zabel P; Schultz H; Vollmer E; Goldmann T; Lang DS
Rom J Morphol Embryol; 2010; 51(4):647-53. PubMed ID: 21103621
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
27. Molecular targeted therapy in lung cancer.
Fujioka N; Bitterman PB
Minn Med; 2012 Oct; 95(10):38-41. PubMed ID: 23193704
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
29. HMGA2 overexpression in non-small cell lung cancer.
Meyer B; Loeschke S; Schultze A; Weigel T; Sandkamp M; Goldmann T; Vollmer E; Bullerdiek J
Mol Carcinog; 2007 Jul; 46(7):503-11. PubMed ID: 17477356
[TBL] [Abstract][Full Text] [Related]
30. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
[TBL] [Abstract][Full Text] [Related]
31. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
32. Personalized therapy for non-small cell lung cancer: hype or clinical reality?
Wigle DA
Semin Thorac Cardiovasc Surg; 2011; 23(1):30-5. PubMed ID: 21807296
[No Abstract] [Full Text] [Related]
33. Lung cancer biomarkers: present status and future developments.
Cagle PT; Allen TC; Olsen RJ
Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.
Johnson ML; Patel JD
Semin Oncol; 2014 Feb; 41(1):93-100. PubMed ID: 24565583
[TBL] [Abstract][Full Text] [Related]
35. The role of BRCA1 in non-small cell lung cancer.
Gachechiladze M; Skarda J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Sep; 156(3):200-3. PubMed ID: 23069884
[TBL] [Abstract][Full Text] [Related]
36. DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.
Nogueira A; Assis J; Catarino R; Medeiros R
Pharmacogenomics; 2013 Apr; 14(6):689-700. PubMed ID: 23570471
[TBL] [Abstract][Full Text] [Related]
37. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
38. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
Codacci-Pisanelli G; Frati L; Mini E
J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
[No Abstract] [Full Text] [Related]
39. Molecular prognostication of non-small cell lung cancer.
Tsao MS; Jablons DM
Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
[No Abstract] [Full Text] [Related]
40. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?
Booton R; Blackhall F; Kerr K
Thorax; 2011 Apr; 66(4):273-5. PubMed ID: 21345972
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
